Spero Therapeutics (SPRO) Net Margin (2016 - 2025)
Historic Net Margin for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to 135.69%.
- Spero Therapeutics' Net Margin fell 42700.0% to 135.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 106.94%, marking a year-over-year decrease of 1134100.0%. This contributed to the annual value of 143.04% for FY2024, which is 1688100.0% down from last year.
- Spero Therapeutics' Net Margin amounted to 135.69% in Q3 2025, which was down 42700.0% from 12.01% recorded in Q2 2025.
- In the past 5 years, Spero Therapeutics' Net Margin registered a high of 212.54% during Q4 2022, and its lowest value of 1456.5% during Q1 2022.
- Its 5-year average for Net Margin is 392.68%, with a median of 236.07% in 2025.
- Examining YoY changes over the last 5 years, Spero Therapeutics' Net Margin showed a top increase of 12120300bps in 2022 and a maximum decrease of -11920500bps in 2022.
- Over the past 5 years, Spero Therapeutics' Net Margin (Quarter) stood at 999.49% in 2021, then surged by 121bps to 212.54% in 2022, then tumbled by -65bps to 74.96% in 2023, then crashed by -281bps to 135.65% in 2024, then decreased by 0bps to 135.69% in 2025.
- Its Net Margin was 135.69% in Q3 2025, compared to 12.01% in Q2 2025 and 236.07% in Q1 2025.